A clinical study on paclitaxel plus cisplatin combined therapy in treatment of advanced non-small cell lung cancer

Objective: To evaluate the effect and side-effect of combined chemotherapy with paclitaxel(PTX) plus cisplatin(DDP) in the treatment of advanced non-small cell lung cancer(NSCLC).Methods: Thirty-four patients with advanced NSCLC received PTX 135 mg/m² by intravenous infusion on d₁,and DDP 75 mg/m² by intravenous infusion on d_2-4.The treatment was repeated every 21 days,up to 2 cycles.Results: Thirty-four patients were evaluable for efficacy,with an overall rate of 41.2%.The response rate of squamous cell carcinoma was no significant difference to that of adenocarcinoma.And there was also no significant difference between the Ⅲ stage patients and the Ⅳ stage patients(P>0.05).But the response rate of primary treatment was significantly different to that of relapse treatment(P<0.05).The main toxicities were myelosuppression,nausea and vomiting,and other side effects were mild.Conclusions: A high response rate can be obtained in advanced NSCLC by PTX plus DDP.PTX plus DDP combined therary is a promising antitumor protocol with tolerable toxicity.